Studies have found elevated levels of SREBP1c in patients with NAFLD [54] along with an expected rise in hepatic TG levels in mice genetically engineered to overexpress the protein [55]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.